Video Experimental Relacionado
Updated: May 10, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
La activación del factor Xa del factor V es de suma importancia para iniciar el sistema de coagulación: lecciones de
Tim J Schuijt1, Kamran Bakhtiari, Sirlei Daffre
1Center for Experimental and Molecular Medicine, University of Amsterdam, Meibergdreef 9, Room L01-145, 1105 AZ, Amsterdam, The Netherlands. T.J.Schuijt@outlook.com
Circulation
|July 3, 2013
Resumen
Las garrapatas usan una proteína salival, TIX-5, para inhibir la coagulación de la sangre al bloquear la activación del factor V mediada por el factor Xa. Este descubrimiento ofrece nuevos conocimientos sobre la coagulación y las interacciones entre garrapatas y huéspedes.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología Molecular Biología Molecular
- La hemostasis también es conocida como hemostasis.
Sus antecedentes:
- La coagulación de la sangre implica el factor Va (FVa) y el factor Xa (FXa) que forman el complejo de la protrombinasa.
- Los modelos actuales sugieren que la trombina inicia la activación de la VF, pero esto es objeto de debate.
Objetivo del estudio:
- Investigar las propiedades anticoagulantes de la proteína salival de garrapata recombinante TIX-5.
- Elucidar el mecanismo molecular de TIX-5 en la inhibición de la coagulación del huésped.
Principales métodos:
- Se produjo el TIX-5 recombinante.
- Estudió los efectos anticoagulantes en el plasma, la sangre completa y los sistemas purificados.
- Evaluación de los efectos in vivo con el uso de conejos inmunes TIX-5.
Principales resultados:
- TIX-5 inhibe específicamente la activación de FV mediada por FXa, dirigiéndose al dominio FV B.
- La activación de FV mediada por FXa es crucial para el plasma y la coagulación de la sangre.
- La alimentación de garrapatas está deteriorada en conejos inmunes al TIX-5, lo que confirma la relevancia in vivo.
Conclusiones:
- Las garrapatas emplean TIX-5 para inhibir de manera única la coagulación del huésped.
- Proponer un modelo de coagulación revisado donde FXa media directamente la activación de FV durante la iniciación.
- La activación de la VF mediada por la trombina puede ser restringida por el fibrinógeno y los inhibidores.
Videos de Conceptos Relacionados
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...